Home › Diffuse Large B-Cell Lymphoma › Wisconsin
Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa Wisconsin
20 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Wisconsin.
Mga Lungsod sa Wisconsin
Opisyal na teksto ng pag-aaral (English)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Gunderson Health System ( Site 9563), La Crosse
- SSM Health Dean Medical Group ( Site 0140), Madison
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- SSM Health Dean Medical Group ( Site 0106), Madison
- Medical College of Wisconsin ( Site 0103), Milwaukee
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT06890884Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Duluth Clinic Ashland, Ashland
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- at 18 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT06649812A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07101328A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Medical College of Wisconsin, Milwaukee
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07188558A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07226843A Study of ARC-02 in B-cell NHL
- Froedtert & Medical College of Wisconsin, Milwaukee
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT07691606Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Wisconsin, Milwaukee
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT06131801Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- ThedaCare Regional Cancer Center, Appleton
- Duluth Clinic Ashland, Ashland
- Aurora Cancer Care-Southern Lakes VLCC, Burlington
- at 22 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT05890352Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
- Mayo Clinic Health System-Eau Claire Clinic, Eau Claire
- Mayo Clinic Health System-Franciscan Healthcare, La Crosse
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 20, 2026 · NCT06834373Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Medical College of Wisconsin, Milwaukee
- at 1 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 15, 2026 · NCT05633615Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Mayo Clinic Health System-Eau Claire Clinic, Eau Claire
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT03418038Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Nagre-recruitPhase 2
Edad 70 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT06594939Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Medical College of Wisconsin, Milwaukee
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
- Froedtert & the Medical College of Wisconsin, Milwaukee
Nagre-recruitPhase 1
Edad 18 hanggang 81 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT05990465Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Medical College of Wisconsin, Milwaukee
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
- Medical College of Wisconsin and Froedtert Hospital, Milwaukee
Nagre-recruitPhase 1/2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Peb 23, 2026 · NCT04186520Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Nob 10, 2025 · NCT03375619Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.